WallStSmart

Eton Pharmaceuticals Inc (ETON)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 3881% more annual revenue ($3.18B vs $79.95M). UTHR leads profitability with a 41.9% profit margin vs -5.8%. UTHR earns a higher WallStSmart Score of 67/100 (B-).

ETON

Hold

35

out of 100

Grade: F

Growth: 7.3Profit: 4.5Value: 5.0Quality: 5.0

UTHR

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 9.0Value: 10.0Quality: 7.8
Piotroski: 5/9Altman Z: 7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ETON.

UTHRUndervalued (+62.9%)

Margin of Safety

+62.9%

Fair Value

$1282.02

Current Price

$541.60

$740.42 discount

UndervaluedFair: $1282.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ETON2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
82.7%10/10

Revenue surging 82.7% year-over-year

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

UTHR4 strengths · Avg: 9.5/10
Profit MarginProfitability
41.9%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
45.0%10/10

Strong operational efficiency at 45.0%

Altman Z-ScoreHealth
7.3010/10

Safe zone — low bankruptcy risk

EPS GrowthGrowth
24.5%8/10

Earnings expanding 24.5% YoY

Areas to Watch

ETON4 concerns · Avg: 2.3/10
Market CapQuality
$598.57M3/10

Smaller company, higher risk/reward

Price/BookValuation
24.6x2/10

Trading at 24.6x book value

Return on EquityProfitability
-18.2%2/10

ROE of -18.2% — below average capital efficiency

EPS GrowthGrowth
-12.6%2/10

Earnings declined 12.6%

UTHR1 concerns · Avg: 4.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ETON

The strongest argument for ETON centers on Revenue Growth, Operating Margin. Revenue growth of 82.7% demonstrates continued momentum.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.

Bear Case : ETON

The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio.

Key Dynamics to Monitor

ETON profiles as a hypergrowth stock while UTHR is a mature play — different risk/reward profiles.

ETON carries more volatility with a beta of 1.24 — expect wider price swings.

ETON is growing revenue faster at 82.7% — sustainability is the question.

UTHR generates stronger free cash flow (173M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (67/100 vs 35/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eton Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?